AAPS Guidelines and Protocol for COVID-19: Early Treatment Can Reduce COVID-19 Hospitalizations and Deaths

Dec. 31, 2020 /PRNewswire/ -- A peer-reviewed updated summary of COVID-19 early-treatment best practices was published in Reviews in Cardiovascular Medicine, an interdisciplinary scientific, open access journal.



This international collaboration — comprised of physicians, like lead author Peter McCullough, MD, outlines the urgency of "prompt early initiation of sequenced multi-drug therapy (SMDT) … to stem the tide of hospitalizations and death."

The authors explain:

The early stage of viral replication provides a therapeutic window of tremendous opportunity to potentially reduce the risk of more severe sequelae in high risk patients. Precious time is squandered with a 'wait and see' approach … resulting in unnecessary hospitalization, morbidity, and death.… In newly diagnosed, high-risk, symptomatic patients with COVID-19, SMDT has a reasonable chance of therapeutic gain with an acceptable benefit-to-risk profile.

Included in the paper is a "sequential multidrug treatment algorithm" and summaries of the rationale and evidence for each component.

In an alert issued to members, the Association of American Physicians and Surgeons, urges physicians to "share this new article with your colleagues, any contacts you have in the media, and with leaders in your community." "To overcome the increasing censorship of lifesaving information, it is imperative that everyone pitch in to see that this manuscript is distributed as widely as possible," AAPS states.

The article also includes a list of the numerous countries around the world that are encouraging early treatment. The authors contrast the situation in countries including the U.S. where "the current failure of government support for randomized clinical trials evaluating widely available, generic, inexpensive therapeutics, and the lack of instructive outpatient treatment guidelines (U.S., Canada, U.K., Western EU, Australia, some South American Countries), clinicians must act according to clinical judgement and in shared decision making with fully informed patients."

"Until the pandemic closes with population-level herd immunity potentially augmented with vaccination, early ambulatory SMDT should be a standard practice in high risk and severely symptomatic acute COVID-19 patients beginning at the onset of illness," conclude the authors.

AAPS has represented physicians of all specialties in all states since 1943. The AAPS motto is omnia pro aegroto, meaning everything for the patient.

SOURCE: Association of American Physicians and Surgeons (AAPS)

Related Links:
**********************************

Listing of early home-based treatment kits provided for acute COVID-19 illness by various countries:

Algeria: Chloroquine/HydroxychloroquineBelayneh, A. (2020) Off-Label Use of Chloroquine and Hydroxychloroquine for COVID-19 Treatment in Africa Against WHO Recommendation. Research and Reports in Tropical Medicine 11, 61-72.

Argentina: Ivermectin
Mega, E. R. (2020) Latin America’s embrace of an unproven COVID treatment is hindering drug trials. Nature586, 481-482. 

Brazil: Hydroxychloroquine, Ivermectin, Azithromycin (Vitamin D and zinc only for those who can afford)
Ministério da Saúde. Acesse o Plano Nacional de Operacionalização da Vacina contra a Covid-19. Available at: https://www.gov.br/saude/pt-br (Cited: 11 November, 2020).

Bangladesh: Ivermectin, Doxycycline
Trial Site News. Ivermectin usage accelerates while the need for data is real: how about an ivermectin registry? Trial Site News. Available at: https://www.trialsitenews.com/ivermectin-usage-accelerates-while-the-need-for-data-is-real-how-about-an-ivermectin-registry/ (Cited: 11 November, 2020).

China: Chloroquine/Hydroxychloroquine 
Fan, L., Jiang, S., Yang, X., Wang, Z. and Yang, C. (2020) COVID-19 Drug Treatment in China. Current Pharmacology Reports, 1-9.

Egypt: Chloroquine/Hydroxychloroquine

France: Hydroxychloroquine, Azithromycin, and Lopinavir-Ritonavir
Gérard, A., Romani, S., Fresse, A., Viard, D., Parassol, N., Granvuillemin, A., Chouchana, L., Rocher, F. and Drici, M. D. (2020) “Off-label” use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Thérapie75, 371-379.

India: Hydroxychlorquine, Ivermectin, alone or in combination with other drugs
Vora, A., Arora, V. K., Behera, D. and Tripathy, S. K. (2020) White paper on Ivermectin as a potential therapy for COVID-19. Indian J Tuberc67, 448-451.

Korea: Hydroxychloroquine
Hong, K. S., Jang, J. G., Hur, J., Lee, J. H., Kim, H. N., Lee, W. and Ahn, J. H. (2020) Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication. Journal of Infection and Chemotherapy52, 396-402.

Spain: Patients who are already taking hydroxychloroquine within or outside of clinical trials for COVID-19 as well as patients undergoing chronic treatment with these drugs should continue taking them and, in any case, maintain their usual follow-ups with their doctors
Agencia Española de Medicamentos y Productos Sanitarios. Información acerca del uso de hidroxicloroquina para el tratamiento de COVID-19. Available at https://www.aemps.gob.es/informa/notasinformativas/laaemps/2020-laaemps/informacion-acerca-del-uso-de-hidroxicloroquina-para-el-tratamiento-de-covid-19/ (Acessed: 11 November, 2020).

Taiwan: Hydroxychloroquine
Sheng, W. H. (2020) Interim Guidelines for Clinical Management of SARS-CoV-2 Infection (5th edition). Available at: https://fightcovid.edu.tw/cdc-guidelines/clinical-management (Acessede: 11 November, 2020).

USA: Association of American Physicians and Surgeons Home COVID-19 Treatment Guide recommends adjuvant neutraceuticals, and sequenced multidrug therapy by prescription
https://aapsonline.org/covidpatientguide/


Disclaimer: All information presented is not intended to replace the guidance from your medical doctor. Please discuss with your doctor before you take any supplement or medication related to COVID-19.



Comments